Proud to have been part of this team effort. Great early signal for #RTIRE in intermediate-risk prostate cancer — excited to see where the phase II data and #IRRADIANT trial take us next.
Phase 1 #RTIRE: focal IRE + reduced-dose RT (32.5 Gy/5 fx) for intermediate risk prostate cancer:View quoted post on X
✅ 10/10 negative biopsies at 12 mo
✅ No grade 3–5 AEs
Promising, NOT definitive.
pubs.rsna.org/doi/epdf/10.11…
Next: phase 2 data final report in 42 patients → ongoing randomized #IRRADIANT trial (cancer.gov/research/parti…).